WO2018058221A1 - Combinação anti-angiogênica de compostos despigmentantes - Google Patents
Combinação anti-angiogênica de compostos despigmentantes Download PDFInfo
- Publication number
- WO2018058221A1 WO2018058221A1 PCT/BR2017/050285 BR2017050285W WO2018058221A1 WO 2018058221 A1 WO2018058221 A1 WO 2018058221A1 BR 2017050285 W BR2017050285 W BR 2017050285W WO 2018058221 A1 WO2018058221 A1 WO 2018058221A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- angiogenic
- topical composition
- acid
- composition according
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/445—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof aromatic, i.e. the carboxylic acid directly linked to the aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
Definitions
- the present invention relates generally to an anti-angiogenic combination consisting of depigmenting compounds as well as a topical composition containing the same, its preparation process, uses and methods.
- the skin is complex organ which consists of two main parts.
- the outer part, called the epidermis is organized in layers of cells.
- the inner part, called the dermis is composed of an upper papillary layer and a lower reticular layer.
- the junction or interface between the epidermis and the dermis is irregular, the dermis has projections, the dermal papillae, which fit into recesses of the epidermis, increasing the cohesion between the two layers.
- Skin lightening or depigmentation is desirable when consumers are concerned about inadvertent skin darkening and consequent appearance problems.
- Melasma is considered the most common and most visible skin pigmentary disease, which affects the face and represents a huge aesthetic discomfort.
- VEGF vascular endothelium growth factor
- iNOS inducible nitric oxide synthase
- VEGF is reported to be related to increased melanocyte activity, since melanocytes are endowed with functional VEGF receptors, whereas iNOS causes NO emission and therefore tyrosinase stimulation and melanin transfer to melanosoma.
- Nanoparticles carrying active compounds have recently been used as a carrier active in cosmetic, dermatological or pharmaceutical compositions. However, maintaining the process conditions for formulating such products (compared when the assets are not included as nanoparticles) results in less stable products.
- the present invention has surprisingly achieved anti-angiogenic effects by the use of certain combined depigmenting compounds, and generally relates to the depigmenting and anti-angiogenic effects obtained by a specific combination of depigmenting compounds.
- depigmenting compounds which consists essentially of arbutin, trans-4- (aminomethyl) cyclohexacarboxylic acid and retinol, which are particularly combined in specific proportions / amounts, and which may be carried in a stable anti-angiogenic topical composition at room temperature.
- the present invention relates to anti-angiogenic topical compositions comprising the combination of depigmenting compounds according to the present invention, particularly carried on one or more nanoparticles.
- a process for obtaining a stable topical composition comprising at least one nanoparticle carrying active compounds, particularly depigmenting compounds.
- the present invention also relates to a A process for preparing or manufacturing a room temperature stable topical composition comprising one or more depigmenting compounds contained in nanoparticles.
- the present invention relates to the use of the combination of depigmenting compounds according to the present invention in the preparation of a depigmenting and anti-angiogenic cosmetic or dermatological product, as well as a method for improving skin penetration and retention .
- the present invention relates to an anti-angiogenic combination consisting of depigmenting compounds selected from arbutin, trans-4- (aminomethyl) cyclohexacarboxylic acid and retinol.
- Arbutin is a glycoside, which is a glycosylated hydroquinone, extracted from bearberry, a plant of the genus Arctostaphylos. Arbutin is known to inhibit tyrosinase, thus preventing the formation of melanin, which justifies its use as a depigmenting agent, ie aimed at skin bleaching.
- Trans-4- (aminomethyl) cyclohexacarboxylic acid, or tranexamic acid is a compound used to treat or prevent excessive blood loss from trauma, surgery, and in various medical conditions such as hemophilia and heavy menstrual bleeding. More recently, its depigmenting effect on the treatment of melasma has been found by oral administration.
- Retinol or vitamin Al
- Retinol is one of the animal forms of vitamin A. Structurally, it is an alcohol-functional diterpenoid. Retinol helps the skin to create better, healthier cells, has antioxidant effect and increases collagen production. Its uses on the skin are known, for example, As an exfoliator, to reduce fine lines and wrinkles, depigment the skin, act as an anti-aging agent, open pores, and treat sun-damaged skin.
- depigmenting compounds according to the present invention in addition to a skin depigmenting effect, surprisingly promotes anti-angiogenic effect, as evidenced by the reduction in synthesis of VEGF and iNOS proteins by their use, shown in the following examples. forward.
- This anti-angiogenic effect indicates action on the vascular component of melasma and its depigmenting properties suggest its use in its prevention and treatment.
- the depigmenting compounds of the combination of the present invention are present in the following proportions:
- the present invention relates to a stable anti-angiogenic topical composition containing the following percentages of depigmenting compounds relative to the total weight of the composition:
- Arbutin about 0.3% to about 0.7%, preferably about 0.5%;
- Trans- 4- (aminomethyl) cyclohexacarboxylic acid about 0.3% to about 0.7%, preferably about Retinol: about 0.15 to about 0.31%, preferably about 0.225%.
- the anti-angiogenic topical composition object of the present invention comprises nanoparticulate-borne depigmenting compounds, which enable the delivery of said compounds to the skin-epidermis interface in a controlled manner, having the following advantages:
- Controlled release in the context of the present invention is at least up to about 50% of the loaded active after 8 hours of application. More preferably, the controlled release is at least up to about 70% of the loaded active after 8 hours of application.
- the nanoparticles employed in the topical compositions of the present invention are lipid, consisting of a solid and liquid lipid complex.
- the addition of liquid lipids to solid lipids alters the formation of lipid crystals, which minimizes the expulsion of active compounds during storage.
- the lipids used to prepare lipid nanoparticles are triglycerides, fatty acids, waxes and glycerides. partially hydrolysed.
- the nanoparticles of the topical composition are preferably coated with a surfactant, preferably nonionic surfactant, and exhibit excellent dispersion in the topical composition, substantially 4.25 x 12 ⁇ m.
- a surfactant preferably nonionic surfactant
- nanoparticles due to their small size and good dispersion, nanoparticles have an occlusive, non-comedogenic effect on the skin and are responsible for a reduction in water loss and consequent increase in hydration.
- This occlusive effect allows for greater skin hydration and not only influences its appearance and condition, but also facilitates the permeation of the carrier compounds.
- the structure of the biocompatible nanoparticles can be influenced by the nonionic surfactant and carrier actives, and their resulting stability measured by their zeta potential.
- the nanoparticles of the topical composition of the present invention still have a potential zeta of substantially -16.2 mV.
- the nanoparticle according to the present invention may, in particular embodiment, comprise from about 0.01 to about 20% of a loaded compound by weight of the nanoparticle.
- nanoparticles with any type of trigger associated with the release of the active compounds such as enzymatic, temperature, acidity, friction, osmosis, or any other.
- the nanoparticles according to the present invention release the active compounds by enzymatic trigger, that is, the skin's own enzymes that activate their release.
- the hydrophilic active compounds are confined within the particle and surrounded by a lipid wall.
- nanoparticles are particles between 100 and 500 nanometers. Particularly suitable nanoparticles with a size of 270 nanometers are suitable.
- nanoparticles are advantageously produced from ingredients selected from the group consisting of linoleic acid, oleic acid, triglycerides, caprylic acid, capric acid, polysorbates and / or PPG-15 stearyl ether, steareth, Avena sativa seed oil, Arnica montana flower oil.
- ingredients and process free of organic solvents, results in a non-comedogenic and low genotoxicity biocompatible nanoparticle.
- the anti-angiogenic topical compositions according to the present invention contain arbutin and trans-4- (aminomethyl) cyclohexacarboxylic acid compounds in the same nanoparticles and the retinol compound in a different nanoparticles.
- the anti-angiogenic topical composition of the present invention may contain other depigmenting or skin lightening agents, for example selected from one or more of kojic acid, caffeic acid, ascorbic acid or derivatives thereof, ellagic acid, azelaic acid, linoleic acid, alpha hydroxy acid, beta hydroxy acid, 4-n-butylresorcinol, chamomile extract, placenta extract, niacin, niacinamide, hexamidine, resveratrol, hydroquinone, retinol palmitate, trimethylglycine or retinoic acid.
- depigmenting or skin lightening agents for example selected from one or more of kojic acid, caffeic acid, ascorbic acid or derivatives thereof, ellagic acid, azelaic acid, linoleic acid, alpha hydroxy acid, beta hydroxy acid, 4-n-butylresorcinol, chamomile extract, placen
- topical anti- The angiogenic agent of the present invention may contain one or more active compounds other than depigmentants, such as sunscreen, healing agent, antibiotic, anti-aging agent, toning agent, antioxidant, which may or may not be carried within the nanoparticles.
- active compounds other than depigmentants such as sunscreen, healing agent, antibiotic, anti-aging agent, toning agent, antioxidant, which may or may not be carried within the nanoparticles.
- the basis of the anti-angiogenic topical composition of the invention comprises excipients known per se in the prior art as humectants, emulsifiers, rheological additives, stabilizers, thickeners, emollients, antioxidants, pH correctors, and any others necessary for their topical use. . It may also contain ingredients not essentially necessary for the anti-angiogenic performance of the composition but which appeal to the user such as perfume, pigment, dye, preservative, etc.
- the anti-angiogenic topical composition may comprise from about 0.01 to about 10% humectants, from about 0.01 to about 2% viscosity controllers, from about 0%. 0.01 to about 5% emulsifiers, from about 0.01 to about 0.05% of stabilizers, from about 1 to about 20% emollients, from about 0.001 to about 1% antioxidants, about 0.01 to about 1% scavengers, about 0.01 to about 1% pH correctors and / or about 0.01 to about 2% preservatives.
- the anti-angiogenic topical composition of the invention may be presented as an emulsion, solution, dispersion, suspension, foam, gel, aerosol or any other that permits its topical application.
- Preferred is the presentation of the composition in gel-cream form, understood herein as an emulsion with a high percentage of aqueous phase and low or very low oil content.
- compositions of the present invention may be topically applied to mammalian skin for depigmentation and / or bleaching, according to appropriate protocol, for example, each month, each week, each day, every day, twice a day, during the day, at night or the like.
- skin lightening refers generally to the lightening, lightness, whitening, and / or uniformity of skin tone, skin color, and / or skin tone, and / or to reduce yellowing, and / or for the brightening and / or disappearance of hyperpigmented markings and / or lesions that include, but are not limited to, pigmented spots, melanin spots, age signs, sun spots, senile lentigo, freckles, lentigo simplex, pigmented solar keratosis.
- skin lightening also refers to increased skin radiance, brightness, translucency and / or luminescence and / or obtaining a more radiant, bright, translucent or luminous skin tone appearance or skin tone less yellow or pale.
- skin lightening refers to lightening and balancing skin tone, increasing skin radiance and / or lightening age signs.
- compositions of the present invention are advantageously prepared by a preparation process carried out at room temperature, comprising the appropriate mixture of its ingredients, followed by the addition of the nanoparticulate depigmenting actives at the end under gentle stirring.
- “Proper mix of its ingredients” means mixing according to the person skilled in the art, following known practice of process conditions, stirring speed, vacuum usage, ingredient addition sequence, etc. For example, in the case of emulsions, the skilled artisan knows that it is not advantageous practice to mix all aqueous and oily ingredients from the outset, but to prepare them separately for later mixing.
- ambient temperature range between 18 and 42 2 C.
- millimeter agitation is meant less agitation than that used during the process, providing adequate homogenization of the mixture without causing sudden changes in viscosity.
- the agitation is reduced from about 40 to about 70% with respect to the strongest agitation, more particularly about 60% reduction with respect to the more intense agitation. strong.
- the process of the invention aims at obtaining stable topical composition in the form of emulsion, dispersion, suspension, solution, foam, gel, aerosol, etc.
- the process of the invention aims at obtaining a stable topical composition based on an oil-in-water emulsion, particularly of nonionic characteristic.
- the process of the invention is directed to the preparation of product in the form of gel-cream, understood as an emulsion with high percentage of aqueous phase and low or very low oil content.
- a “stable" topical composition is one that typically does not exhibit substantial variations in appearance, viscosity, color or odor in prolonged storage of, for example, 6 months.
- the process of the present invention is particularly suitable for the preparation of a gel cream comprising the nanoparticulate retinol, arbutin and trans-4- (aminomethyl) cyclohexacarboxylic acid contained in nanoparticles, notably when they are delivered to the skin by enzymatic triggering.
- the hydrophilic actives are confined within the particle and surrounded by a lipid wall.
- the present invention relates to a process for preparing a stable topical gel cream composition comprising the combination of arbutin depigmentant active compounds, trans-4-acid.
- (aminomethyl) cyclohexacarboxylic acid and retinol which are contained in active carrier lipid nanoparticles, performed at room temperature, comprising the appropriate mixing of their ingredients under gentle stirring at 40 rpm combined with more potent stirring at 800 rpm, followed by addition at the end. of the depigmenting compounds contained in nanoparticles, under agitation of 40 rpm.
- the invention relates to the cosmetic and / or dermatological use of a combination of depigmentants in the preparation of a stable topical anti-angiogenic composition, depigmenting arbutin, trans-4- (aminomethyl) cyclohexacarboxylic acid and retinol.
- Example 1 Two embodiments of gel-cream formulation as shown in table 1 below.
- Example 2 Carrying out gel-cream formulation as shown in table 2 below.
- Example 3 Carrying out gel-cream formulation as shown in table 3 below.
- Step 1 Ingredients 1 to 5 were added to the main reactor separately and homogenized at 40 rpm with the aid of the anchor propeller only. At this stage a viscous cream gel is formed.
- Step 2 In an auxiliary tank the ingredients 6 were mixed under stirring until their dispersion was complete.
- Step 3 The dispersion of step 2 was poured into the main reactor with the aid of vacuum and homogenized for 10 minutes while maintaining the vacuum.
- Step 4 Ingredients 7 to 10 were individually added and homogenized for 5 minutes after each addition with the aid of anchor propeller (40 rpm), and turrax (800 rpm).
- Step 5 Depigmentants 11 and 12 were added individually. At this stage the stirring speed was drastically reduced and the mixture was homogenized. for 15 minutes only with anchor propeller (40 rpm), and apply vacuum.
- the viscosity achieved ranges from 40,000 to 100,000 cps.
- formulation 1 promoted the reduction of the synthesis of VEGF and IOS proteins in cultured dermal fibroblasts, indicating anti-angiogenic property.
- the composition has been shown to reduce melanin production in both melanocyte and human skin cultures. Depigmentation was revealed by decreased endothelial levels, PAR2, and tyrosinase activity when compared to cultures exposed to UV radiation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112019005296A BR112019005296B8 (pt) | 2016-09-27 | 2017-09-27 | Combinação anti-angiogênica, composição tópica anti-angiogênica, processo de preparação de uma composição tópica estável e uso de uma combinação |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRBR1020160224160 | 2016-09-27 | ||
BR102016022425-0A BR102016022425A2 (pt) | 2016-09-27 | 2016-09-27 | Carreador lipídico nanoestruturado |
BR102016022421-7A BR102016022421A2 (pt) | 2016-09-27 | 2016-09-27 | Método para melhorar a penetração na pele de um agente farmacologicamente ativo, método para entregar ativos à interface de junção derme- epiderme e processo para o tratamento das camadas superiores da epiderme |
BR102016022420-9A BR102016022420A2 (pt) | 2016-09-27 | 2016-09-27 | Composição tópica, uso cosmético da composição e composição tópica e dermatológica |
BR102016022419-5A BR102016022419A2 (pt) | 2016-09-27 | 2016-09-27 | Combinação anti-angiogênica, composição tópica anti-angiogênica e uso de uma combinação |
BR102016022422-5A BR102016022422A2 (pt) | 2016-09-27 | 2016-09-27 | Composição despigmentante para aplicação tópica |
BRBR1020160224250 | 2016-09-27 | ||
BRBR1020160224217 | 2016-09-27 | ||
BRBR1020160224195 | 2016-09-27 | ||
BR102016022416-0A BR102016022416A2 (pt) | 2016-09-27 | 2016-09-27 | Processo de fabricação de produto tópico estável |
BRBR1020160224225 | 2016-09-27 | ||
BRBR1020160224209 | 2016-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018058221A1 true WO2018058221A1 (pt) | 2018-04-05 |
Family
ID=61762433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2017/050285 WO2018058221A1 (pt) | 2016-09-27 | 2017-09-27 | Combinação anti-angiogênica de compostos despigmentantes |
Country Status (2)
Country | Link |
---|---|
BR (1) | BR112019005296B8 (pt) |
WO (1) | WO2018058221A1 (pt) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006249010A (ja) * | 2005-03-11 | 2006-09-21 | Ltt Bio-Pharma Co Ltd | 皮膚外用剤 |
US8486374B2 (en) * | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US20160008246A1 (en) * | 2014-07-11 | 2016-01-14 | Mary Kay Inc. | Sunscreen compositions and methods of their use |
-
2017
- 2017-09-27 WO PCT/BR2017/050285 patent/WO2018058221A1/pt active Application Filing
- 2017-09-27 BR BR112019005296A patent/BR112019005296B8/pt active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8486374B2 (en) * | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
JP2006249010A (ja) * | 2005-03-11 | 2006-09-21 | Ltt Bio-Pharma Co Ltd | 皮膚外用剤 |
US20160008246A1 (en) * | 2014-07-11 | 2016-01-14 | Mary Kay Inc. | Sunscreen compositions and methods of their use |
Also Published As
Publication number | Publication date |
---|---|
BR112019005296A2 (pt) | 2019-06-04 |
BR112019005296B1 (pt) | 2022-06-14 |
BR112019005296B8 (pt) | 2023-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108451837B (zh) | 一种美白液晶组合物及其制备方法和应用 | |
RU2764769C2 (ru) | Продукты для наружного применения с двухфазной системой | |
WO2009127058A1 (en) | Skin care compositions and methods of use thereof | |
JP2008526963A (ja) | 過度に色素沈着した皮膚を処置するための組成物および方法 | |
US9468597B1 (en) | Stabilized L-ascorbic acid skin serum | |
BRPI0622226A2 (pt) | composiÇço de clareamento de pele para pele hiperpigmentada | |
KR20180027375A (ko) | 식물 태지 성분을 포함하는 피부 보습용 화장료 조성물 | |
BRPI1010464A2 (pt) | composiÇÕes que compreendem um inibidor de nfkb e um promotor de tropoelastina | |
CN109846740B (zh) | 皮肤护理组合物及其制备方法和应用 | |
BR102013030307A2 (pt) | Sistemas de dois componentes para liberar ácido ascórbico estabilizado | |
JPH0899820A (ja) | 皮膚外用剤 | |
KR102359729B1 (ko) | 유화 제형의 끈적임 저감 및 투명도 향상용 화장료 조성물 | |
KR20160120355A (ko) | 피부-윤광 화장품 조성물 | |
JP2005120023A (ja) | 皮膚外用剤 | |
JP2010511021A (ja) | 色素脱失剤としてのガンマアミノ酪酸の利用 | |
TWI523666B (zh) | 包含歐洲百合萃取物之組成物及其用途(二) | |
CN102525851B (zh) | 含有欧洲百合提取物的组合物及其用途 | |
JP2007332078A (ja) | オゾン溶存グリセリン溶液を含む化粧料、医薬部外品、医薬(医薬品)等の外用剤 | |
CN108578257B (zh) | 一种苦橙花油丹皮酚水包油纳米乳及其制备方法 | |
JP2005336095A (ja) | 外用組成物 | |
JP2009001575A (ja) | オゾン溶存グリセリン溶液を含む化粧料、医薬部外品、医薬(医薬品)等の外用剤 | |
WO2018058221A1 (pt) | Combinação anti-angiogênica de compostos despigmentantes | |
JPH03200708A (ja) | 皮膚外用剤 | |
JP4976714B2 (ja) | 皮膚色不均一性改善剤、皮膚外用剤、化粧料及び皮膚色不均一性改善方法 | |
JP2009256326A (ja) | 美白剤、及び皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17854274 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019005296 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112019005296 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190318 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17854274 Country of ref document: EP Kind code of ref document: A1 |